HOME >> MEDICINE >> NEWS
FDA approves new HIV protease inhibitor, Lexiva (TM)

Research Triangle Park, N.C., Oct. 21, 2003 GlaxoSmithKline (GSK) today announced that the Food and Drug Administration has granted marketing clearance for Lexiva (fosamprenavir calcium) (Lex-ee'-va, formerly GW433908, or 908), a new protease inhibitor (PI) for the treatment of HIV infection in adults in combination with other antiretroviral medications. The following points should be considered when initiating therapy with Lexiva/ritonavir (Lexiva/r) in PI-experienced patients: the PI-experienced patient study was not large enough to reach a definitive conclusion that Lexiva/r and lopinavir/ritonavir are clinically equivalent. Once-daily administration of Lexiva plus ritonavir is not recommended for PI-experienced patients. Lexiva was co-discovered by GSK and Vertex Pharmaceuticals (Nasdaq: VRTX). Lexiva, a PI that can be taken once or twice daily without food or water restrictions, has been evaluated in clinical trials with both PI-experienced and antiretroviral therapy (ART)-nave HIV patients.

Lexiva may be dosed three different ways: 1) two 700mg tablets twice daily (BID), 2) two 700mg tablets once daily (QD) in combination with two 100mg capsules of ritonavir QD (Lexiva/r QD), or 3) one 700mg tablet BID in combination with one 100mg capsule of ritonavir BID (Lexiva/r BID). For PI-experienced patients, the recommended dose is one 700mg tablet BID in combination with one 100mg capsule of ritonavir BID.

"The drug's QD and BID dosing options with no food or water restrictions, and a low pill burden demonstrate GSK's ongoing commitment to providing flexible anti-HIV therapies for patients," said Doug Manion, M.D., vice president of clinical development and medical affairs at GSK.

More than 1,200 people both ART-nave and PI-experienced patients participated in three Phase III trials to test the safety and efficacy of Lexiva with and without ritonavir. In all three trials, study drugs were taken as part of combination therapy that incl
'"/>

Contact: Elaine Salewske
esalewske@pcipr.com
312-558-1770
Public Communications Inc.
21-Oct-2003


Page: 1 2 3 4 5

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves EPZICOM
6. FDA approves new labelling for Seroquel in bioplar mania
7. FDA approves Enbrel to treat psoriasis
8. FDA approves Climara Pro to treat menopause symptoms
9. FDA approves new approach to schizophrenia treatment
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... , ... Cardiothoracic surgeons at Allegheny General Hospital (AGH), part ... (CMU) to develop a new heart monitoring device designed to serve as an ... AGH/CMU team was recently awarded a “Trailblazer” grant from the National Institutes of ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... recently donated 1,400 N95 face masks to medical first responders across the United ... to make donations of personal protective equipment (PPE) medical centers , ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado State University ... career-relevant, and affordable online education – is proud to announce its new master’s ... first of its kind in the nation, the 60-credit hour program is designed ...
(Date:8/31/2020)... Hawaii (PRWEB) , ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with ... people on the planet are in a state of panic, experiencing deep anxiety, immense stress, ... Right now, a solution is timely when most people on the planet are experiencing a ...
(Date:8/31/2020)... NEW HAVEN, Conn. (PRWEB) , ... August 31, ... ... a medical device intended to improve outcomes for patients with advanced heart failure, ... Innovation Research (SBIR) grant in the amount of $555,358 from the National Heart, ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... ... August 26, 2020 , ... Hero Life Sciences announced today that ... 3 ply surgical disposable face masks and N95 respirators in its manufacturing plant located ... challenge that most Americans are facing in trying to find quality disposable face masks ...
(Date:8/26/2020)... ... 26, 2020 , ... NucleusHealth, LLC, a provider of market ... and Chief Executive Officer effective immediately. Dr. Vishal Verma, the previous CEO, will ... , Mr. Hooton, a seasoned business executive, joined the company in February ...
(Date:8/26/2020)... SAN DIEGO (PRWEB) , ... August 25, 2020 ... ... opening of its brand new Stem Cell Treatment Center to give ... stress free environment. With this announcement, ProgenCell establishes its leadership in the field ...
Breaking Medicine Technology:
Cached News: